Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Status:	Active, not recruiting
Conditions:	Breast Cancer, Prostate Cancer, Cancer, Cancer, Brain Cancer, Blood Cancer, Lymphoma, Hematology
Therapuetic Areas:	Hematology, Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	11/16/2018
Start Date:	April 25, 2011
End Date:	November 30, 2019

A Phase 1a/1b, Multicenter, Open Label, Dosefinding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual Dna-pk and Tor Kinase Inhibitor, Cc-115, Administered Orally to Subjects With Advanced Solid Tumors and Hematologic Malignancies

The main purpose of this first human study with CC-115 is to assess the safety and action of
a new class of experimental drug (dual DNA-PK and TOR kinase inhibitors) in patients with
advanced tumors unresponsive to standard therapies and to determine the appropriate dose and
tumor types for later-stage clinical trials. The bioavailability of tablet and capsule
formulations under fasting and fed conditions will also be evaluated in some patients.

Latest amendment clarifies that Chronic Lymophocytic Leukemia (CLL) includes T-cell
Prolymphocytic Leukemia (T-PLL). Prior treatment with some drugs targeting mTOR, P13K and
related pathways is now permitted.

Inclusion Criteria:

- Histologically-confirmed advanced solid tumor, chronic lymphocytic leukemia, small
lymphocytic lymphoma, T-cell prolymphocytic leukemia, Non-Hodgkin Lymphoma or multiple
myeloma

- Progressed or not tolerated standard therapy, and no further standard therapy is
available

- Archival and screening tumor biopsy

- Eastern Cooperative Oncology Group Performance Status: 0 or 1

- Adequate organ function

Exclusion Criteria:

- Prior cancer-directed modalities or investigational drugs within 4 wks or 5 half
lives, whichever is shorter

- Symptomatic brain metastases (prior treatment and stable metastases are allowed)

- Acute or chronic renal disease or pancreatitis

- Diarrhea ≥ Grade 2, impaired gastrointestinal absorption

- Impaired cardiac function

- History of diabetes requiring treatment, glucose >126 mg/dL, Glycated hemoglobin
(HbA1c) ≥6.5%

- Peripheral neuropathy ≥ Grade 2

- Known Human Immunodeficiency Virus (HIV) infection, chronic hepatitis B or C (unless
associated with hepatocellular cancer)

- Pregnant, inadequate contraception, breast feeding

- Most concurrent second malignancies

- Part B only: Prior treatment with agents targeting both mammalian target of rapamycin
(mTOR) complexes (dual mammalian target of rapamycin complex 1/2 inhibitors) and/or
PI3K/AKT pathways. However, prior treatment with isolated target of rapamycin complex
1 (TORC1) inhibitors (eg., rapalogs) is allowed in both parts of this study.

We found this trial at

sites

Sarah Cannon Research Institute Drug Development Unit

Nashville, Tennessee 37203

from

Nashville, TN